Cancer Cell. 2020 Oct 12;38(4):449-451. doi: 10.1016/j.ccell.2020.09.008.
ABSTRACT
An article in the New England Journal of Medicine reveals a significant reduction of incidence-based mortality of non-small cell lung cancer in the U.S. and attributes this improvement to the approval of targeted therapies.